The differential effects of low dose and high dose concanavalin A on cytokine profile and their importance in liver injury

Inflammation Research

Volumn 55, Issue 4, 2006, Pages 144-152

  Xu, X ^a   Wei, H ^a   Dong, Z ^a   Chen, Y ^a   Tian, Z ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Concanavalin A (ConA); Fas; IFN ; IL 4; IL 6; Liver injury

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CONCANAVALIN A; CYTOKINE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 6; MESSENGER RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE SYSTEM; INFLAMMATION; LIVER CELL; LIVER FAILURE; LIVER INJURY; LOW DRUG DOSE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TOXIC HEPATITIS; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD95; APOPTOSIS; CONCANAVALIN A; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE EXPRESSION PROFILING; HEPATITIS; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE ACTIVATION; MALE; MICE; T-LYMPHOCYTES;

EID: 33745598546     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-0064-2     Document Type: Article

References (38)

1. Tiegs G. Experimental hepatitis and role of cytokines. Acta Gastroenterol Belg 1997; 60: 176-9.
2. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203.
3. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factor and protection by interleukin 6. J Exp Med 1994; 179: 1529-37.
4. Schümann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N et al. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 2000; 157: 1671-83.
5. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97: 5498-503.
6. Jaruga B, Hong F, Sun R, Radaeva S, Gao B. Crucial Role of IL-4/ STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes. J Immunol 2003; 171: 3233-44.
7. Bonder CS, Ajuebor MN, Zbytnuik LD, Kubes P, Swain MG. Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis. J Immunol 2004; 172: 45-53.
8. Sass G, Heinlein S, Agli A, Bang R, Schumann J, Tiegs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002; 19: 115-20.
9. Gantner F, Leist M, Lohse AW, Germann P, Tiegs G. Concanavalin A-induced T cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21: 190-8.
10. Küsters S, Gantner F, Künstle G, Tiegs G. Interferon-γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462-71.
11. Mizuhara H, Uno M, Seki N, Yamashita M, Yamaoka M, Ogawa T et al. Critical involvement of interferon-γ in the pathogenesis of T-cell activation associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996; 23: 1608-15.
12. Nicoletti F, Zaccone P, Xiang M, Magro G, Di Mauro M, Di Marco R et al. Essential pathogenetic role for interferon (IFN-)γ in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-γ and prevention by IFN-γ receptor-immunoglobulin fusion protein. Cytokine 2000; 12: 315-23.
13. Toyabe S, Seki S, Iaii T, Takeda K, Shirai K, Watanabe H et al. Requirement of IL-4 and liver NK1+T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997; 159: 1537-42.
14. Nicoletti F, Di Marco R, Zaccone P, Salvaggio A, Magro G, Bendtzen K et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12(IL-12) exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology 2000; 32: 728-33.
15. Louis H, L Moine O, Peny M-O, Quertinmont E, Fokan D, Goldman M, Deviere J. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 1997; 25: 1382-9.
16. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000; 191: 105-14.
17. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-13.
18. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51.
19. Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y. Concanavalin A injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. Hepatology 2004; 40: 1190-6.
20. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002; 110: 1503-13.
21. Sun R, Tian Z, Kulkarni S, Gao B. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 2004; 172: 5648-55.
22. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001; 103: 131-6.
23. Crutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005; 77: 3-15.
24. Kuddus RH, Nalesnik MA, Subbotin VM, Rao AS, Gandhi CR. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes - an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 2000; 33: 725-32.
25. Uemura T, Gandhi CR. Inhibition of DNA synthesis in cultured hepatocytes by endotoxin-conditioned medium of activated stellate cells is transforming growth factor-beta and nitric oxide-independent. Br J Pharmacol 2001; 133: 1125-33.
26. Meng Y, Kang S, So J, Reierstad S, Fishman DA. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol 2005; 96: 462-9.
27. Zheng S-J, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113: 58-64.
28. Nishikage T, Seki S, Toyabe S, Abo T, Kagata Y, Iwai T et al. Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis. J Hepatol 1999; 31: 18-26.
29. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-66.
30. Heyninck K, Wullaert A, Beyaert R. Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. Biochem Pharmacol 2003; 66: 1409-15.
31. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G.. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003; 39: 333-40.
32. Abe M, Akbar F, Hasebe A, Horiike N, Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol 2003; 38: 962-7.
33. Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 2003; 64: 1334-41.
34. Ayroldi E, Zollo O, Cannarile L, D'Adamio F, Grohmann U, Delfino DV et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. Blood 1998; 92: 4212-9.
35. Emilie D, Navratil E, Devergne O, Reynes M, Crevon MC, Samuel D et al. Monokine gene expression in normal human liver: selective involvement of the portal compartment. Liver 1992; 12: 34-41.
36. Scotte M, Daveau M, Hiron M, Delers F, Lemeland JF, Teniere P et al. Interleukin-6 (IL-6) and acute-phase proteins in rats with biliary sepsis. Eur Cytokine Networks 1991; 2: 177-82.
37. Wright RM, Holladay CS, Spangelo BL. Lipopolysaccharide induces interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a novel mechanism. Circ Shock 1993; 41: 131-7.
38. Zhu X-L, Pacheco ND, Dick EJ, Rollwagen FM. Differentially increased IL-6 mRNA expression in liver and spleen following injection of liposome- encapsulated haemoglobin. Cytokine 1999; 11: 696-703.